{
    "organizations": [],
    "uuid": "ca57180bfcb2171e0319e08649a065fc93f93156",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eli-lilly-says-new-data-show-truli/brief-eli-lilly-says-new-data-show-trulicity-combo-treatment-improves-blood-sugar-control-in-type-2-diabetes-patients-idUSFWN1QG0O7",
    "ord_in_thread": 0,
    "title": "BRIEF-Eli Lilly Says New Data Show Trulicity Combo Treatment Improves Blood Sugar Control In Type 2 Diabetes Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Eli Lilly And Co:\n* ELI LILLY SAYS NEW DATA SHOW TRULICITY (DULAGLUTIDE) IN COMBINATION WITH SGLT-2 INHIBITOR IMPROVES BLOOD SUGAR CONTROL IN PEOPLE WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T20:12:00.000+02:00",
    "crawled": "2018-02-27T15:21:18.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "eli",
        "lilly",
        "co",
        "eli",
        "lilly",
        "say",
        "new",
        "data",
        "show",
        "trulicity",
        "dulaglutide",
        "combination",
        "inhibitor",
        "improves",
        "blood",
        "sugar",
        "control",
        "people",
        "type",
        "diabetes",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}